Groundbreaking Pancreatic Cancer Drug Shows Promise in Lung Cancer
Early trial data showed tumors shrank in more than 30% of patients, but researchers said the results are preliminary and resistance has emerged in some cases.
6 Articles
6 Articles
Pancreatic Cancer Drug Rasonque Shows Early Promise Against RAS-Mutated Lung Cancer Too
A drug approved for pancreatic cancer just a week ago is already showing signs it could help treat lung cancer, the world's leading cause of cancer death. Early trial results published in the New England Journal of Medicine found that tumours shrank in more than 30 per cent of lung cancer patients given the drug, called daraxonrasib (brand name Rasonque). Each patient in the small trial had non-small-cell lung cancer, the most common form of the…
FDA-approved pancreatic cancer drug Rasonque shows promise in lung cancer trial
BATON ROUGE — A drug recently approved by the FDA for pancreatic cancer is now showing promise in early-stage lung cancer trials.The drug, Rasonque, was FDA-approved for pancreatic cancer last week. Researchers are now finding it may also be effective against non-small cell lung cancer.A study looked at more than 130 patients with non-small cell lung cancer who had already tried other therapies with little to no success. After taking the daily p…
Groundbreaking Pancreatic Cancer Drug Shows Promise in Lung Cancer
(MedPage Today) -- The landmark oral RAS inhibitor daraxonrasib (Rasonque) showed efficacy in previously treated patients with metastatic RAS-mutant non-small cell lung cancer (NSCLC) in a phase I/II trial. Among 136 patients treated with daraxonrasib...
A New Drug Against Pancreatic Cancer Also Manages to Reduce Lung Tumors in More than 30% of Patients
Treatment with daraxonrasib has been a small revolution in the scientific community for its first results.
Daraxonrasib exhibits ‘encouraging signal’ in RAS -mutant metastatic lung cancer
An oral drug widely expected to transform pancreatic cancer treatment has demonstrated encouraging clinical activity in metastatic non-small cell lung cancer. Daraxonrasib (Rasonque, Revolution Medicines) induced durable responses in patients with previously treated, RAS-mutant NSCLC, according to results of a phase 1/phase 2 dose-escalation and dose-expansion study.
Coverage Details
Bias Distribution
- 80% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
